Patrys Limited (PAB) is focused on the development of
natural human antibody-based therapies for the treatment of
cancer. The company is also exploring opportunities to
deploy its technologies in additional indications, either
internally or through third parties, including
cardiovascular, autoimmune and central nervous system disorders.